Arcellx, Inc. (ACLX)

$62.56

+0.32

(+0.51%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $60.61
    $63.23
    $62.56
    downward going graph

    3.12%

    Downside

    Day's Volatility :4.14%

    Upside

    1.06%

    downward going graph
  • $30.88
    $75.10
    $62.56
    downward going graph

    50.64%

    Downside

    52 Weeks Volatility :58.88%

    Upside

    16.7%

    downward going graph

Returns

PeriodArcellx, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
20.5%
5.9%
0.0%
6 Months
12.61%
5.5%
0.0%
1 Year
84.8%
10.9%
0.0%
3 Years
270.48%
15.6%
-17.0%

Highlights

Market Capitalization
3.5B
Book Value
$9.32
Earnings Per Share (EPS)
-1.03
Wall Street Target Price
79.93
Profit Margin
-38.39%
Operating Margin TTM
-40.27%
Return On Assets TTM
-6.71%
Return On Equity TTM
-12.63%
Revenue TTM
131.7M
Revenue Per Share TTM
2.66
Quarterly Revenue Growth YOY
119.19999999999999%
Gross Profit TTM
0.0
EBITDA
-72.8M
Diluted Eps TTM
-1.03
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.57
EPS Estimate Next Year
-2.12
EPS Estimate Current Quarter
-0.51
EPS Estimate Next Quarter
-0.53

Analyst Recommendation

Buy
    95%Buy
    4%Hold
    0
    0%Sell
Based on 21 Wall street analysts offering stock ratings for Arcellx, Inc.(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
20
19
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 27.77%

Current $62.56
Target $79.93

Technicals Summary

Sell

Neutral

Buy

Arcellx, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arcellx, Inc.
Arcellx, Inc.
14.01%
12.61%
84.8%
270.48%
270.48%
Moderna, Inc.
Moderna, Inc.
-9.73%
21.69%
-3.08%
-61.31%
759.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
2.19%
14.34%
48.43%
82.37%
258.01%
Novo Nordisk A/s
Novo Nordisk A/s
-7.8%
21.53%
62.25%
194.33%
441.74%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.55%
12.21%
36.13%
144.99%
180.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arcellx, Inc.
Arcellx, Inc.
NA
NA
NA
-1.57
-0.13
-0.07
NA
9.32
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.06
32.06
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.67
31.67
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arcellx, Inc.
Arcellx, Inc.
Buy
$3.5B
270.48%
NA
-38.39%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
759.82%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$119.6B
258.01%
32.06
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
441.74%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
180.32%
31.67
39.46%

Institutional Holdings

  • FMR Inc

    10.08%
  • Perceptive Advisors LLC

    7.35%
  • Paradigm Biocapital Advisors LP

    7.14%
  • NEA Management Company, LLC

    7.00%
  • BlackRock Inc

    5.73%
  • SR ONE CAPITAL MANAGEMENT, LP

    4.39%

Corporate Announcements

  • Arcellx, Inc. Earnings

    Arcellx, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

Arcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.

Organization
Arcellx, Inc.
Employees
130
CEO
Mr. Rami Elghandour
Industry
Healthcare

FAQs